1-20 of 117
Keywords: Survival
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology 1–12.
Published Online: 17 January 2024
...Patricia Toquero; Rebeca Mondéjar; Nuria Romero-Laorden; Elena Méndez; Lucía Castillo; Berta Hernández Marín; Olga Donnay; Ramon Colomer Introduction: Older patients (≤75 years) with advanced colorectal cancer (CRC) may have worse survival than non-older patients. We hypothesized that, rather than...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2023) 101 (4): 270–282.
Published Online: 20 April 2023
... < 0.001), and PNI ≥47 (HR, 0.333; 95% CI, 0.212–0.525; p < 0.001) were independently associated with overall survival. Multivariate analysis showed that an α-fetoprotein level ≥100 ng/mL (HR, 1.690; 95% CI, 1.316–2.170; p < 0.001) and PNI ≥47 (HR, 0.696; 95% CI, 0.528–0.918; p = 0.010) were...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2023) 101 (1): 41–48.
Published Online: 24 January 2023
...Hyera Kim; Jin Young Kim; Keon Uk Park Introduction: Current standard chemotherapy for biliary tract cancer (BTC) has limited survival benefits, and the need for targeted therapies is increasing. This study investigated the genetic profiles and clinical implications of BRCA mutations in patients...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2022) 100 (9): 498–504.
Published Online: 11 July 2022
...: The prevalence of sarcopenia was 40.23%. Sarcopenia did not influence dose-limiting toxicity of treatment, hazard ratio (HR) 1.01, 95% CI (0.70–1.47). Sarcopenia was associated with lower progression-free survival (PFS): HR 1.49, 95% CI (0.98–2.26), and lower overall survival (OS): HR 1.67, 95% CI (1.11–2.52...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2022) 100 (10): 536–541.
Published Online: 27 June 2022
... with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6− compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors. Conclusion: In chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2022) 100 (6): 331–336.
Published Online: 15 February 2022
.... The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Trop2 − compared to Trop2 + (89.6% vs. 100.0%; p = 0.288). Conclusion: In chRCC, Trop2 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2022) 100 (3): 131–139.
Published Online: 25 January 2022
... neuroendocrine tumors (GEP-NETs) are octreotide long-acting release (Sandostatin LAR) and somatuline depot (Lanreotide). The study’s objective was to compare progression-free survival (PFS) and overall survival (OS) of patients (pts) with GEP-NETs treated with somatuline or octreotide LAR. Pts and Methods: Pts...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2022) 100 (3): 173–181.
Published Online: 20 January 2022
...%), cancer treatment toxicity (43%), and comorbidities (37%). The median overall survival (OS) after ICU admission was 2.6 months; 15% of the patients died during the ICU stay. Poor PFs for OS were PS >1 before ICU admission ( p = 0.007) and ICU admission for the cancer itself ( p < 10 −3 ). After ICU...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2021) 99 (12): 747–755.
Published Online: 28 September 2021
... progression-free survival was 12.4 months, with 68.7% of patients alive at 12 months. The developing of hypertension predicted increased progression-free survival at multivariate analysis (HR, 0.128; 95% CI, 0.03–0.59; p = 0.008). Conclusions: Tivozanib showed good activity and favorable safety profile...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2021) 99 (9): 589–600.
Published Online: 17 June 2021
.... We evaluated the associations between TLR5 and TLR7 tissue expressions, clinicopathologic variables, and survival. Using the Kaplan-Meier method, we generated survival curves, determining significance using the log-rank test. Univariate and multivariate survival analyses relied on the Cox...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2020) 98 (12): 884–888.
Published Online: 01 December 2020
... adenocarcinoma with low Her2 protein expression (2+ by IHC) whose tumors were evaluated for gene amplification of ERBB2 by fluorescence in situ hybridization (FISH). All patients received first-line therapy, and trastuzu­mab was added according to Her2 status. We compared overall survival (OS), progression-free...
Journal Articles
Journal Articles